Generate Biomedicines (GENB) Stock Price, News & Analysis

Company Overview

Generate Biomedicines is a biotechnology company that uses generative artificial intelligence, machine learning and protein engineering to design novel protein-based medicines. Its platform is intended to identify and develop therapeutic proteins with desired biological properties, potentially shortening the time required to discover new drug candidates.

The company’s research activities focus on applying computational biology and laboratory experimentation to create medicines for a range of diseases, including conditions in immunology, inflammation, oncology and other areas of significant unmet medical need. Its work includes the discovery and development of engineered protein therapeutics and related drug candidates.

Generate Biomedicines was founded through Flagship Pioneering and is headquartered in Somerville, Massachusetts. The company operates primarily in the United States and collaborates with pharmaceutical and biotechnology organizations to advance its generative biology technology and potential therapies.

Key Stats

• Today's Range: $12.20 to $13.39
• 50-Day Range: $12.09 to $20.38
• 52-Week Range: $11.00 to $22.67
• Volume: 744,175 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $26.40
• Consensus Rating: Moderate Buy

Generate Biomedicines Stock Analysis - MarketRank™

Generate Biomedicines scored higher than 59% of companies evaluated by MarketBeat, and ranked 403rd out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Generate Biomedicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Generate Biomedicines has a consensus price target of $26.40, representing about 99.8% upside from its current price of $13.21.

Amount of Analyst Coverage

Generate Biomedicines has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Generate Biomedicines are expected to grow in the coming year, from ($2.29) to ($2.15) per share.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.96% of the float of Generate Biomedicines has been sold short.

Short Interest Ratio / Days to Cover

Generate Biomedicines has a short interest ratio ("days to cover") of 7.99.

Change versus previous month

Short interest in Generate Biomedicines has recently increased by 20.41%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Generate Biomedicines does not currently pay a dividend.

Dividend Growth

Generate Biomedicines does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 1.16

News Sentiment

Generate Biomedicines has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Generate Biomedicines this week, compared to 2 articles on an average week.

Search Interest

Only 4 people have searched for GENB on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

5 people have added Generate Biomedicines to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Generate Biomedicines insiders have not sold or bought any company stock.

Percentage Held by Institutions

Generate Biomedicines has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/27/2026
• 3rd Annual Guggenheim Healthcare Innovation Conference: 11/09/2026
• Jefferies Global Healthcare Conference: 11/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:GENB
• CIK: 2100782
• Web: www.generatebiomedicines.com
• Phone: (888) 469-0055
• Fax: N/A
• Employees: 312
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Generate Biomedicines: $26.40
• High Price Target: $30.00
• Low Price Target: $22.00
• Potential Upside/Downside: +99.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.63
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Optionable
• Beta: N/A